Allarity Therapeutics (ALLR) Shares Outstanding (2020 - 2026)
Allarity Therapeutics' (ALLR) quarterly Shares Outstanding (Entity) came in at $19.0 million in Q1 2026, up 70.74% YoY from $11.1 million in Q1 2025, and up 32.36% on a QoQ basis from $14.4 million in Q4 2025.
Allarity Therapeutics (ALLR) Shares Outstanding (2020 - 2026) Analysis & Trends
Allarity Therapeutics (ALLR) has 7 years of Shares Outstanding (Entity) data on file, last reported at $19.0 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 70.74% year-over-year to $19.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.0 million (up 70.74% YoY) and the FY2025 annual result came in at $14.4 million, up 794.78% from the prior year.
- Shares Outstanding (Entity) climbed to $19.0 million in Q1 2026, from $14.4 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $19.0 million in Q1 2026 to a low of $10.0 in Q1 2022.
- A 5-year average of $4.7 million and a median of $5842.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) advanced 20.0% — and 2025, when it soared 190706.61%.
- Tracing ALLR's Shares Outstanding (Entity) over 5 years: stood at $11.0 in 2022, then soared by 30063.64% to $3318.0 in 2023, then soared by 48332.46% to $1.6 million in 2024, then jumped by 794.78% to $14.4 million in 2025, then jumped by 32.36% to $19.0 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $19.0 million (Q1 2026), $14.4 million (Q4 2025), and $14.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Allarity Therapeutics | 22.75 Mn | 22.75 Mn | - | 15.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.97 Mn |
| Dec 31, 2025 | 14.38 Mn |
| Sep 30, 2025 | 14.74 Mn |
| Jun 30, 2025 | 15.54 Mn |
| Mar 31, 2025 | 11.15 Mn |
| Dec 31, 2024 | 1.61 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 499,253.00 |
| Mar 31, 2024 | 5,842.00 |
| Dec 31, 2023 | 3,318.00 |
| Sep 30, 2023 | 4,124.00 |
| Jun 30, 2023 | 621.00 |
| Mar 31, 2023 | 32.00 |
| Dec 31, 2022 | 11.00 |
| Sep 30, 2022 | 12.00 |
| Jun 30, 2022 | 11.00 |
| Mar 31, 2022 | 10.00 |
| Dec 31, 2021 | 8.00 |
| Sep 30, 2021 | 9.00 |
| Jun 30, 2021 | 6.00 |